Answers are grounded in this paper and cite their sources.
Movement disorder management and therapy are rapidly evolving, owing to an ever-deeper understanding of disease biology and the discovery of new tools for diagnosis and treatment. With this narrative review, we aim to explore emerging therapeutic approaches for movement disorders, with a focus on Parkinson’s disease (PD) and other movement-related pathological conditions, including Huntington’s disease (HD), essential tremor (ET), and dystonia. This review encompasses preclinical research and human trials, providing a comprehensive overview of the current landscape. Several promising therapeutic strategies have emerged, particularly in the realm of precision medicine for PD associated with GBA and LRRK2 gene mutations. Additionally, innovative immunotherapies and drugs targeting misfolded α-synuclein are under investigation. These approaches have the potential to influence disease progression and improve patient outcomes. The landscape of pharmacological treatments for movement disorders is both complex and diverse, with substantial progress made over the years. While current treatments effectively manage motor symptoms, they fall short of providing a definitive cure and are limited by nonmotor symptoms and potential side effects. Novel techniques, such as gene therapy, stem cell therapy, and infusion therapies, offer promising avenues for future research.
No takes yet. Share an insight, caveat, or question.
Siraj et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: